SCHEMBL20292829

SCHEMBL20292829

Clc1ccnc2ccc(-c3c[nH]c4ncccc34)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1B Q9Y463 2/20 1.00
DYRK1A Q13627 17/20 0.60
CDC7 O00311 3/20 0.54
GSK3B P49841 3/20 0.54
ROCK2 O75116 2/20 0.54
MAP4K4 O95819 2/20 0.54
PIM1 P11309 2/20 0.54
PRKACA P17612 2/20 0.54
CDK2 P24941 2/20 0.54
HIPK2 Q9H2X6 2/20 0.54
CLK4 Q9HAZ1 2/20 0.54
IRAK4 Q9NWZ3 1/20 0.54
CDK9 P50750 2/20 0.53
DAPK3 O43293 1/20 0.53
PRKD3 O94806 1/20 0.53
PAK4 O96013 1/20 0.53
FLT3 P36888 1/20 0.53
CSNK1A1 P48729 1/20 0.53
CLK2 P49760 1/20 0.53
CDK7 P50613 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12281648 0.84 DYRK1B (0.73) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL30233270 0.84 DYRK1B (0.73) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL20292820 0.83 DYRK1B (0.71) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL20292912 0.82 DYRK1B (0.70) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL26174558 0.82 DYRK1B (0.69) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL20318990 0.81 DYRK1B (0.68) DYRK1BDYRK1ACDK2CDK9CCNT1
SCHEMBL20292748 0.81 DYRK1B (0.68) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL20292991 0.81 DYRK1B (0.67) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL8939833 0.79 CDC7 (0.67) DYRK1BDYRK1ACDC7GSK3BROCK2
SCHEMBL31006512 0.78 DYRK1A (0.66) DYRK1BDYRK1AGSK3BCDK9CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases FELICITEX THERAPEUTICS, INC. (US) 2020-03-03 US claimed
EP-3558321-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2019-10-30 EP claimed
WO-2018119039-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 WO claimed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US claimed
EP-4183786-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2023-05-24 EP disclosed
EP-4183786-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2023-05-24 EP disclosed
EP-3558321-B1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS INC (US) 2023-02-01 EP disclosed
EP-3558321-B1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS INC (US) 2023-02-01 EP disclosed
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases FELICITEX THERAPEUTICS, INC. (US) 2020-03-03 US disclosed
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases FELICITEX THERAPEUTICS, INC. (US) 2020-03-03 US disclosed
EP-3558321-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES Felicitex Therapeutics, Inc. (US) 2019-10-30 EP disclosed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US disclosed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US disclosed
WO-2018119039-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 WO disclosed
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 US disclosed
WO-2018119039-A1 DERIVATIVES OF QUINOLINES AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES FELICITEX THERAPEUTICS, INC. (US) 2018-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10577365-B2 Derivatives of quinoline as inhibitors of DYRK1A and/or DYRK1B kinases DYRK1A, DYRK1B, DYRK2 DYRK1B 2/4885DYRK1A 1/4885CDC7 460/4885
US-20180179199-A1 DERIVATIVES OF QUINOLINE AS INHIBITORS OF DYRK1A AND/OR DYRK1B KINASES DYRK1A, DYRK1B, DYRK2 DYRK1B 2/4885DYRK1A 1/4885CDC7 460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.